VERIGRAFT generates personalized tissue-engineered transplants for use in regenerative medicine. The company’s unique technology platform turns donated allogeneic (“foreign”) tissue into an autologous-like (“personalized”) tissue and thus avoids transplant rejection and the need for life-long immunosuppression.
VERIGRAFT has raised €1.2M across 1 funding round from 1 investor, most recently a Grant round in Feb 2025. Based in Gothenburg, Sweden; active in Healthtech. Data as of 7 Aug 2026.
Timing: overdue vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2025-02-14 | Grant | €1.2M |
| EuroStars |
| View deal → |
